Technical and clinical outcomes of thrombectomy in patients with acute medium vessel occlusion and large vessel occlusion; sub-analyses of Japan Trevo registry

改良兰金量表 医学 优势比 闭塞 置信区间 冲程(发动机) 子群分析 内科学 导管 大脑中动脉 外科 入射(几何) 第一次通过 缺血性中风 缺血 机械工程 物理 算术 光学 数学 工程类
作者
Shuntaro Kuwahara,Kazutaka Uchida,Nobuyuki Sakai,Hiroshi Yamagami,Hirotoshi Imamura,Masataka Takeuchi,Manabu Shirakawa,Fumihiro Sakakibara,Koichi Haraguchi,Naoto Kimura,Kentaro Suzuki,Shinichi Yoshimura
出处
期刊:Journal of the Neurological Sciences [Elsevier BV]
卷期号:459: 122956-122956 被引量:2
标识
DOI:10.1016/j.jns.2024.122956
摘要

Background Little is known about endovascular therapy (EVT) for patients with medium vessel occlusion (MeVO) and more work is needed to establish its efficacy and to understand hemorrhagic complications. Methods We analyzed the Japan Trevo Registry, which enrolled patients with acute stroke who underwent EVT using Trevo Retriever alone or in combination with an aspiration catheter. The primary outcome was effective reperfusion, and the secondary outcome was modified Rankin scale 0–2 at 90 days. Safety outcomes, including intracranial hemorrhage (ICH), were evaluated using a subgroup analyses focused on any ICH. Results Among 1041 registered patients, 1025 patients were analyzed. 253 patients had MeVOs, and the majority (89.3%) had middle cerebral artery segment 2 (M2). The median National Institutes of Health Stroke Scale scores at admission were 15 and 19 for the MeVO and LVO groups (p < 0.0001). The primary outcome was 88.9% in MeVO vs. 91.8% in LVO group: adjusted odds ratio (aOR) [95% confidence interval (CI)] 0.60 [0.35–1.03], p = 0.07, and the secondary outcome was 43.2% vs. 42.2%, and the aOR [95%CI] was 0.70 [0.48–1.002], p = 0.051. However, the incidence of any ICH was more prominent in MeVO than in LVO group (35.7% vs. 28.8%, aOR [95%CI] 1.54 [1.10–2.15], p = 0.01). In subgroup analyses, the incidences of any ICH in MeVO group were generally higher than those in LVO group. Conclusions The effective reperfusion rate did not differ significantly between MeVO and LVO groups. Future development of devices and treatments for MeVO with fewer hemorrhagic complications is desirable.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Alie完成签到 ,获得积分10
3秒前
doudou发布了新的文献求助10
4秒前
lu完成签到 ,获得积分10
4秒前
斯文败类应助专业中药人采纳,获得10
6秒前
情怀应助doudou采纳,获得10
7秒前
Tiffany完成签到,获得积分10
8秒前
8秒前
hyfwkd完成签到,获得积分10
8秒前
大模型应助wang采纳,获得10
10秒前
于蒙完成签到,获得积分10
11秒前
傻傻的盼曼完成签到,获得积分10
11秒前
小苒Ran完成签到 ,获得积分10
11秒前
大溺完成签到 ,获得积分10
12秒前
13秒前
family完成签到,获得积分10
13秒前
丘比特应助大气靳采纳,获得10
14秒前
14秒前
14秒前
华鹰完成签到,获得积分10
14秒前
Nov完成签到 ,获得积分10
15秒前
16秒前
16秒前
17秒前
fbwg发布了新的文献求助10
18秒前
19秒前
21秒前
明理囧完成签到 ,获得积分10
23秒前
23秒前
26秒前
情怀应助任侠传采纳,获得10
27秒前
olivia完成签到,获得积分10
27秒前
wang发布了新的文献求助10
28秒前
ding应助蒋美桥采纳,获得10
29秒前
清和漾完成签到,获得积分10
30秒前
30秒前
所所应助科研通管家采纳,获得10
30秒前
解方程组完成签到,获得积分10
30秒前
30秒前
ay应助科研通管家采纳,获得10
30秒前
慕青应助科研通管家采纳,获得10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Cardiovascular Research and Medicine(2e) 820
自動車の空力技術 800
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 化学工程 工程类 有机化学 物理 复合材料 生物化学 内科学 细胞生物学 基因 遗传学 免疫学 冶金 光电子学 癌症研究
热门帖子
关注 科研通微信公众号,转发送积分 7779842
求助须知:如何正确求助?哪些是违规求助? 9320095
关于积分的说明 20374730
捐赠科研通 7367383
什么是DOI,文献DOI怎么找? 3319559
关于科研通互助平台的介绍 2467518
邀请新用户注册赠送积分活动 2335294